ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
Alzamend Neuro, Inc.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 10, 2026
$1.33+0.03 (+2.31%)
Close on Oct 19, 2026
- Market cap
- $5.96M
- P/E (TTM)
- –
- Dividend yield
- –
Alzamend Neuro statistics
Financials through Jul 31, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Alzamend Neuro | Industry median |
|---|---|---|
| Market Cap | $6.42M | $166.30M |
| Enterprise Value | -$1.17M | $88.19M |
| PB Ratio | 1.11 | 2.03 |
| P/TBV Ratio | 1.11 | 2.29 |
Income (trailing twelve months)
| Measure | Alzamend Neuro | Industry median |
|---|---|---|
| Operating Income | -$9.09M | -$21.40M |
| Net Income | -$9.10M | -$22.46M |
| EBITDA | -$9.09M | -$16.91M |
| EPS (Diluted) | -$2.28 | -$0.83 |
Returns
| Measure | Alzamend Neuro | Industry median |
|---|---|---|
| Return on Equity (ROE) | -163.2% | -53.2% |
| Return on Assets (ROA) | -122.4% | -40.9% |
Balance sheet
| Measure | Alzamend Neuro | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $7.59M | $61.43M |
| Net Cash (Debt) | $7.59M | $15.35M |
| Net Cash Per Share | $1.57 | $0.66 |
| Equity (Book Value) | $5.80M | $49.09M |
| Book Value Per Share | $1.20 | $1.37 |
| Tangible Book Value | $5.80M | $23.52M |
Financial position
| Measure | Alzamend Neuro | Industry median |
|---|---|---|
| Interest Coverage | -1480.55 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Alzamend Neuro | Industry median |
|---|---|---|
| Operating Cash Flow | -$6.84M | -$12.35M |
Efficiency
| Measure | Alzamend Neuro | Industry median |
|---|---|---|
| Profits Per Employee | -$2.27M | -$703.34K |
| Employee Count | 4 | 74 |
Dividends and yields
| Measure | Alzamend Neuro | Industry median |
|---|---|---|
| Earnings Yield | -141.7% | -23.3% |
Shares
| Measure | Alzamend Neuro | Industry median |
|---|---|---|
| Shares Outstanding | 4,825,720 | 58,127,000 |
| Shares Change (QoQ) | 13.4% | 0.54% |
| Float | 4,447,750 | 49,136,700 |
| Shares Held by Insiders | 7.83% | 11.6% |
| Shares Held by Institutions | 56.4% | 59.4% |
Scores
| Measure | Alzamend Neuro | Industry median |
|---|---|---|
| Altman Z-Score | -13.63 | -0.22 |
Calculated by StockData from Alzamend Neuro's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.